vasopressin n llln'l il il'l ft tlfleuu fnl'l gl0fi'ufi p37-44.pdf ·...
TRANSCRIPT
KKU. Vet. J. Vol. 16 No.2 May - August 2006 37
Vasopressin I
Vasopressinl
cl 6) 9rl u6l 9)?l'l { [ 6t o n llln'l T [[ Il ['u il'l ? u u ? ht u u Ft I Ft ta
tlfleuu Fnl'l gl0fi'ufi
Alternative Drug for Cardiopulmonary Arrest
rTrfl eri.:rru-
Patchanee Sringam
nlr;u-':tquuetei'uuorl4qorarulovTufi rflunrryinqoroianrrrfir.lfiifl rflarfionrrr.-r X
t oo &q
t - "3
d d a ai j : u a^tTl.t}ll\lJ?'100:'ln']::00T?o11.111.[FlutLnvfla?a'1illn Q.]Nn-]:flnulttrtor0rntru0q:rnr::o9lT'tql
otnnttve-.tnairr rloorluurfitd'un*ltnr:yir.:ruro.:ra-'llo:-]oounrealortv{fruduainrry:ln66oqsi .q.^' ra a A Lq r ev ^ v a aepinephrine q{ilr[utilil:J5rurn*lnaonaanarnHiLo rrsinr:[riursl,tn6irirnqzun{r.]L€lu.t flo
-i q e A q e X u q o q eL q e d ^ Y atillJnl:[T00nTtauLl-inn''rtJ[1.iot4'] [ottnrrr LuHr Lotoutirzueo.]ury o.:uu vasopressirr 6.luilud d a iu, oqe d o
dnufrlrr.ttdonfr"Lrivir"Lvirffozundr.:t6u{e*tndirr Ieu vasopressin vfrlv{rffon'i:uoqiradr.rrrn
to.:unao;fiooue,.tlurdorfiovTrir.:nru fizunrfinriouqionr:Hereiito.lunoorfioouo{'lufl-xlouoyvl 'Vi ,d a 6t - Y a ju , a-'Lq urqi'tilffzunqianr:uoo?lO.runoornoq[ro.]Luflero.r o*.:riurjtHrrui6oofi"lljrfiu.rarorrrn;u-']lqA;XQ.l [ililflit
,', u1l1:[] ,
firrtfovfinr:6n:*rrrnrururfiotv{nr:ud'hnr:vfr.:rutarvi:to rJoo rrnyalo.:tv{f,u
6uainTrrJn6 (cardiopulmonary cerebral resuscitation; CPCR) tan-tnll:u-ltoraqoroi'urint- 6r u d , , yaHUel14'lu"[ovlufr (cardiopulmonary arrest; CPA) iroiri.:vwiroqr:rnr::oq6iqei']uln?t-.tluyl't.l
nlrttv\rfttnr#flrtrilnri lXass and Haskins, 1992; Wingfield and Van Pett, 1992; Bauew,
1997; Willmcs et al., 2002) Ios"[uvrr.:n1ril?'rvrdfi#qrtntrrsofiiqil:rsJril s-1s% eiruriorunlU
?1'1.1fln?ttllvtunu'Lrjrurn odr.:'[:frq']e,r Wingfield and Van Pelt (1992) Ttu.l'tu'j'lfqiln'trraqldAo@o-AdoT?fltuqt,tl 4.1% Luttru1 9.6% arnflurrrnsrril?frflnl?r CPA o"ruru 169 srfruny s2 dtqq
u.'A- n'rfll1r6r:T?yru1 nrurflqtrL?{ytufl'tflqi ruurrnurnulauuriu a.tiLa.t o.toutrriu 40002
Department of Physiology, Faculty of Veterinary Medicine, Khon Kaen University, Khon Kaen, 40002
q
3B x'r:dr:dYn?rrl\yran'tdFli sJ?. flfi to qriufi 2 ylqunlnil - firnrnt zs+g
c.ifl'lsJo'loiu
"lulruvfr Kass and Haskins (1992) wujrfqr:rnr::oo6iotuq#1 g% 'luuurur
q
2.3% fitu#'itfi.rt14er?o.r cPA ovrrqnqirrriu:vH'ir.:nuriu#o{Iouvru'irtuouo:fioriuqrJ'rotnqq
qrrretfiorJnGto.:uoocrtfioouorluu-rlo e'rutu#q{ni'lulrnufiorornoxrilfiqilnGro{n#rrrdo
vYrtorrorn-nrfioitrurilra-rlorauoroiu (asystole) nrrru-r'[ov{o.roir.rrsiuin (ventricutar fibrillation)4
ttflsT1\aTuUotsll{ (pulseless electrical activity) (Ballew, 1997; Waldrop et al., 2004)\4 a d a Lo
rrqiadrr'L:fforlo5:ivrurllO.:n1:rfifi cPA oruafioun-r.itueruun;#o{ qirriunr:finu'rnt:d'qn1r
cpntusrulolnr:'[d'n-o{ileno{ 6.rlvidoernfirijurj:rlurfiLrnyr"rtunr.rnr:unrrfunr#qruilnda
rjnfinr:vir cPCR Hn-.:nrrv CPA oril:rnoroi'lu g liuqau6o nr:d'lu6iqrrdord'uA Fr , q eA 6l d 4 a& , da Y A <, Yry.3tUun]:T'luLuLnonl:u'luL0ltfl::rL]-JHrJl{t'iuuteioeoru n't:T'ru6lqnuarBrtiluluotou61 6l- A 4 6l , da v d^ A *[unlTLTU'Ittfl3tFr:0.1il0tun]TTlUd1n ttnrnt:qttnum.:TooTlo,rr epinephrine iiluurnoniqo ^
t
ilLTLun't:vl't CPCR rrtflutrnrn'ir +o iJ rfiatornlunrry cpA a;rffqntr?u'tuei'torir.lrurn4 d A A ^ oqea alJ0.:Hd0oL00grttgr.M^lTtvn']:frvfleJt0.t1J0.tLfluttflvR-t?tL1-t0tu0t1q0onrLau ?1'tLvtrf5etrr*tnoql
tr.tritrfiorfiaoir.:1 Iqutailr:aro.ruovvirlodqn{ oirriuirrnru6.rfine'lnnlraoufl1{0.rleunr:"i --^
un-.: endogenous epinephrine LLflr norepinephrine virlv{finoqrifiootrq.tyt'ri'l.tfi'tufiftQi'?A 1 - d 14 r av - i . - , - q -i g - Y a o 6l et1l0 LH[a0o Liltnil.]0?u?vvtaternttufr]J0.tLLnrH? L0ttatrulju o,:uu epineohrine 6.lnnureLr [t'
5ld"lulurgd (Swenson and Reece, 1993; Ganong, 2001; Cao et al., 2003)'lunr:vir CPCR
u#rnrry CpA
a{ o d 6l t ( v 6t , jq -iloauiuornnr:frn:grLud'qrironorvruurer:?"LHrifi'Lvir..rnGtunrrr cpA 6a vasopressin1 -i r dt d, & 6l e,rLqutreJa'lnnlTFllill1Jtuil '1996 ir:vol vasopressin g.:luatrn[up.i:-l'lu CPCR nnrrnonr':rCPA (Lindner et al., 1996a) oi.lrfu6.lfinr:ilqna.rtd'vasopressin rijuar:rfirusrmileriufiorrfiil4 vl ra" * X uq a A a j
t6oo'[rJrfiu.rnd'rrurfiorai'l'Loitovsruo.:n:rfl cpn rfiora6nrfiu.]r.tnrfruo''lnnr:l"i'epinephrine
dt American Heart Association (2000) 6'o vasopressin rfJxurfiarlr:nldrrnu epinephrine5f d u q v t v
^ , u Vl ,u dl erl e d u 6t I q d stunrilnl?314? 10fi0{ot.ltouinttsru.:'LtL:u:4.: Lli[rfn:rxn': [qiluottc{urun: Lu{ilrlufrn Lquo]-gl
lti vasopressin o{tu:;eiu class ttn oirraiu epinephrine nno-qodlu class indeterminate, ql -r.'.-r'.'..._ ti q
1on:rtfi t; eirraiutuyn.:#a'tLtv,tl4ricote et at. (2003) urusdrtri'l#vasopressin Lry1l{ epinephrineq d u6l v | tu
^ L6l e Lq u v
^ d v[un:rxnrr;u1[ol{otei].rta''*3n vr1lofiuerei'u n-'r'Lorqiud'rfiqilndunrfrilaruuerrd'u (n1ilfi 1 )
4-- a q u 6' dr " A, X, qe q
frnr:dn:*rlufqimeno':tiJuo'rurururnfi:-i.:fi'jrnr:'Ld vasopressin lunr:vir cpcR tri'zundr 0e
n?ln.1TLT epinephrine (Krismer et al., 2000; Wenzel et al., 2000; Wenzel and Lindner,
2001 ) et-.ltiu:Jnnlrufid.rfi1e4iuilrutfi0d1tfll.[ou?ru'rnrla{ vasopressin tunr:vir cpcRqc)u ar*.r n I ? r c pR rfi a rfl udo ru n air H iu nr:rir l rtd'[unr.: n fi fi n qi o'lil,t'l
KKU. Vet. J. Vol. 16 No.2 May - August 2006 39
o 1 :1 0 fi 1 u fi o { nr rs-q :r riur o.: rr n fi rr ui o ur fi "["fr'[u nr :rir u 6i qi rius,r{
Srou o101noq11N
^t^^^ Ivtdbb I
Class lla
Class llb
Class lll
Class indeterminate
uiu;rirlvY[d'uvr:r rfiunin oiuariu euuir flil::RrBnrn unrn rreJ:J n oe]fru ars9g
r o aL irt ritdtei yr :r r fi ll n-n o r u a rir a uu i r fi rl : v R r t n r n r n r fl 'r'') il ! a a q R-Er@9
r a rirtrald'toirn:r:flv #norunfi auurrfi:l:yR nfin'ril rLf,yq ?'r:Jiln aon-u*9
LNN%8EJ
U , o a d e U ,d , , n e a[il L 0tu::l Llt LTrl {:-13 L:.iulJ:3fry]Dn't}\ t.ilv0'tQn 0 L1|tno0%fl:r El
ndodLU,d,€UUo?\E 111 [O t1 :133JilflnfiIUu1-5lJ1"?'l LtuL1ll-t01+O:-lLtLqn teJ [OhilO
14EJ'l: American Heart Association, 2000
nlilfi t usqrliuaoulr.lnrrrLri'hrfiorfiqnr?ril-xtod'o.lsir.rroiu3n fi-rtqrauerieiu v{':toroi'u"i'rc
fi e:l n 6 unyfr il o:u u e reiu luyn.r #qr uy{ yl Liq
YIEJ,.l: Cole et al., 2003
epinephrine riluurfitd'[unl:yfr CPCR loru epinepnrine n:r{'uvir cx,-adrenergicq
o6lereceptor ttnr B-adrenergic receptor dr^*n'lrnr:q'u{i cl-adrenergic receptor qryir'ldfiooe
q
t6oquer'i6iru:Jnruuoo-r rfluzuolr.i'rfioen#ucilirlorfirudu rrwfinr:n:yqiu p-adrenergic
receptor ortfisJffglrn'rrtei'ull0.rfirtottnvor1ilttr.rlilnl:fir-Loi'rto.rnd'reLrfi'ora-rto virtv{rflerv d iu 'a , ra ! qe q e X u6l ,qra uq
Hn1l.ltfiu.t11 [3.J1\.]11:yfr.to Fl0tililn]T[T00nfltouLLnyiln{{11.tLuna1ilt1aan? [o na LmtnoH? Lo
,ry
Ventricular fi brillation@ Defibrillate - Deliver 2-5 Jlkg (external),
0.5-l J/kg (internal)- Provide up to 3 consecutive shocks.
@ Resume chest compressions- Continue for 60?90 seconds.
@ Drug therapy: Epinephrine (0.01-0.1 mg/kg IV)
orVasopressin (0.8 u/kg IV)
: Lidocaine (2 mg/kg IV)or
: Amiodarone (5-10 mg/kg I\|@ Repeat defibrillation (2 X initial energy).
As1.-stole/Bradvcardi a/pulseless electrical activitl'@ Drug therapy
: Atropine (0.04 mg/kg IV)Lor.ver dose, if palpable pulse
or suspected vagal arrest.
: Epinephrine (0.0f -0.1 mg/kg IV)- May repeat ai 3? 5 minute intervals.
Vasopressin (0.8 u/kg IV)- Civen one time only.
@ Consider transthoracic pacing- Must be instituted early
v d A v v & u6l vt, ; & Yqtq|1,[tT?il9t0.]14?3 nfl1il[1.[0fi'][0 LeJr1.:1U ttfleUnq lactate t1^13.J1J1 ?1.]LU1Jn[3n1Tyt'tltflrflnn
40 xl:flr:#nxul\ruFlldni sJ?. flfi to arirfi 2 y,rquarnxJ - R.rurnr zs+g
nr:vi'r CPCR (Ditchey and Lindenfeld, 1988) , rnrlndnr:tfepinephrine tu CpCn u-.1fiYo,Ariaornquotuoti't.t tdu n:rflnr:vfr CPCR rilurroruru n1:eloilfllro.:?o.t c{,-adrenergic
receptor oia epinephrine qsoqn.ttdrorlno'lrrriJun:e (Willmcs et at., 2002; Johnson, 2003)
utnl epinephrine fteirqrd.l6isr#u:J::rLrru 2040 iurfi 6.roio.r"[v{#ranruq,5"o 1s*un.on and Reece,
1993; Ganong, 2001) tturiofrr'.tu.:ru'ir trirryuer':rruuqnqir.r:yll'irrnr:ld epinephrine
llll'lelLJ'lororu#:ilurqfin.rrfiorr-liurrfiruriu placebo (Woodhouse et al., 1995) 6.:frnr:4_-.- j' y A Aa %dfi n r*'t €l uo ?t ty{ a nt u't ?t ru n ruat u qi o n i I e pi n e p h ri n e
,d.....A:..,,
QYIS llliltJ,llll O$, vasopressin
vasop ress i n riJ u uJ rj'[n ri'a o ih ufr zu fi olutah] vr r n r rTa u frr urlil r ff ut{fi qr o :Ltqisl o.lf i ad 4 F d q
R?1.{?1''lu nl:ufl.l1a.l vasopressin nnfl1Ln}J Loloao[eLnrnolo.:tnoorrottJitrnrt6ao LuunoeaAai radaA&o6-u6oe fr{rfroooeilnr66rlo.rrfr0ertfrtJfruornnirf,loil osmorecepiorstu'lahJnrorar-sud":n:yoi'u
qq' ;- ;4 j F n
on6l a L r11414fl.: vasopressin ttrylflu ttnvtilo:-l5rurn+r6oo"Luunaorfioenon.ro:nniuflou baroreceptor
firao oqrfi oo ttq.ttfinjttosra-rtofioruu drnr:*r*oto.:#ryrurruern baroreceptor virtrifinrruf.Jtv
4vasopresstn ty't 3J1J1-[
tln1Jo.3 vasopressin qiounoorfiao Lfiootnnr:n:r{'uta.t vasopressin- specific V1q
A * ! a a ..6]-?.a a ,L .receptornnR'l&Jt1.[otruutle.]u0ootnoe vlrLdtfronr:uoo':odr.ltrnfloJunoqtfroot[o.]?.1?Tt{ri,'tu
*qifizunrfinriouqiantrfiqrel-xr0.:unoo16aorror'lura*rtounr'[q] truti'o'l*ifiunqionr:unqr-.lro.JHfl0errfioqttq.ltuarua.l oit#u6trfiru:l3annrr6oqlilrfi'u.tfltro.t (Hatdane and Marks, 2002;
Cao et al., 2003) vasopressin qrfiqirnd.:fiiqril:ylrru 10-15 urfi drurun.ir epinephrineX .- rl *l s& d T q vu0no1nu vasopressin fl'ttJtrn [li'Lr,[rrrrrunoerhoq n:ronr[ntunoo0u [eu'[d'turo
eql
tvirnuvi.r 3 il'l.l (Wenzel and Lindner,2001; Johnson, 2003) Ieutus#TrrnrLril?111.nqdo 6l c^ra
ltl.tvl,t1"L]i'[d 6o 0.8 U/kg rdrrr.:Hooorfiaq (Cote et at., 2003)
eiruzuolor vasopressin qionr:riuflgfl'r?v tfiqotnnr:n:rqiuro.t v2 renal receptorA 'q & o q ea 4--.-1 _.- ! , 5q vr -l Avl0 u Ll.lru[uqnnl1jo{'Lqorvir [u'tfrqntrtn0ot,lfrT a.rur ilruzutl.l tflan tufl?u? o.]yto Ln:1ru n^latlud a U - . X o q ey d ra d T o< j X a.i3Jn-lrelelutlulna:Jillnru nrLli:laarrsil:lSilriloqnlurnyfioonLeLnr66rffrufiu n:ruflTretvasopressin tliu nrrtT:ntl16o (diabetes insipidus) zuritrqn6i"[ueirulo.:yiatfl:rilosh]uosJq uY ! itH1{1tflnOuvtil'tu (Swenson and Reece, 1993; Guyton and Hall,2000; Ganong, 2001)
KKU. Vet. J. Vol. 16 No.2 May - August 2006
619' onl: tS vasopressin [U CPCR
arnn'rr#{tnoqir.htra#rn'rlv cPA tv{riornfi'uorufiur'lrJanr:6ruoi'utd'vasopressin,uqi4ql
Iqu Lindner et al. (1996a)1oi'6nr*reiriru CPA o'ruru O0 nu wlnnrt#tLl(uf,rfi.llrn::u'jr.r:rer:u vasopressin fig.rniu:rlluquuiuurfioonflrryir.:ru'[oira.r (return of spontaneousilq
circulation; ROSC) dlel:.ttilalirln-u epinephrine Tou epinephrine fis.:ostrinrrt#rufi'ufr8rnuqio ROSC
nr:6n r*rtu#q {r o n o { d1 }t? l.uJr n il u'j r nr:ld' vasopressi n tv{2 o 6 I q u r ailr r o rir.: 8.:
n:rfl nr:vir cPcR tiJ utr nr uruurn;lv{zu n 6 n'lr epinephrine Hr ntud'rul otrJSilr r*rfi o q fi'[rJri.:n-rtqun:flilo.l (Krismer et a1.,2000; Wenzel et a|.,2000; Wenzel and Lindner,2001)
nr:6n:+'tu?tu't?t1lo.t vasopressin airumno:td'an: unslulqto.t vasopressin fitd'lu#q{q
nonato$:luir.r o.+-o.B u/kg rdunr:finurtusn: cpA o"ruru t7 er-r iluir an:neirufi1d'iuq9qt ' , av--
vasopressin (n=6) :oo6iqr tru:fiqn:nsilfi'lqii:t epinephrine (n=6) rrdr saline placebott .l(n=5) otuyt".tliiler[flolornfi:oul:nluaror airuqn:fitd'iu vasopressin hiyrr:ouI:qrnr.r
A*esilo.ltiloel:?qfloLo'?il magnetic resonance imaging rrqilnrln':rrufio:Jn6rfiu.lrfinriouda nr:
o e f vr,,?1'1"111.t1JO{nnl?.Jtuo [aLillsarunu (mild ataxia) (Wenzel et al., 2000) etlu Kr-ismer et al.
(2000) dnr*rlunn:nrtr cPA fivir cpcn rflurrnrurunu'jrnn:nsirfi'lriYl vasopressin9q
nrrur:ninr+r:se;LqtrsJeiurorunootfiaqrie{tuu-?ioloi'rvirriuutolrnnir 1s mmHg anoer49 a A , Aul-* vteaTiusl?nl?'l?11nlTfln191 ?[wrqn:nnilYj[orL epinephrine fl'uJtrnin]gr:lfruai'.ln6irr'lqirfrur
L YX - t q
T-?etlrl vt-'tfierlrrtoiuro.:Hnoqr6oqrrottufirtorurnn'jr 15 mmHg fioriJusirr-irdrrr noscnlrfin:*rnr:tdvasopressin rr.:orfffinn-upirhu cpA fiyir cpcR riJuirnruru ilu.j'lq,
na-.101n1d'vasopressin luluro 40 u fi''lrJ'r:nylitv{qirJrudru?u B nil frt*ri'otour (LindnerqJ
et al., 1996b) rfior:JSuurfiuuriu'jt{nr:tf vasopressin rrnr epinephrine ylu'jrn'trroofiiqt
frufi low '[u uasopressin ti:-r 3s% tu epinephrine rrflsntrroerfiiqnrEJlu z+ d',lh.r ooz6l-A?"[u
vasopressin nTu 20%Iu epinephrine (Lindner et at., 1997) uonorndfr:ru.:runtrdntglu:J3ll rfi ulnlrtd vasopressin tu#:Jr u cpR unvtu#fl{yrqno.lilu'jrtuerunr:ld'vasopressin"[r.{'zundrvirn-l
epinephrine ei':uluao{vrq0o.w\L'jrnr:'[dvasopressin1fi2n6n'jryr&.: epinephrine
ttnr placebo (Biondi-Zoccai et al., 2003) orir{'l:fferlfi:rlnu'jT'lrjnusrlrrurrqnei.t.Jto.]LdAan:rnr::oqfrin (stieil et at., 2ao1) unv Rosc (it'uri', 2s4g) tur.iilrt:;m.jr.lnr:td
vasopressin L[og epinephrine
41
42 ?'rrdlrd'nxr1\nerFlrdrri il?. fld t6 auTnfi 2 nqunrneJ - fitlnnt zs+g
vasopressi n rfi atd'[unll v cpA virtfiH n o ol rfi o q rro.r 6i'] uil nr ru o qt-": riiuzu otrdlfi o o
'[r.Ju-rrartorrn;:vuuil:rarreirunnrru',nd* ti'.:fit.t,fitorn:roirnr:uqal-?T0.r14oaotfiootto.ri, u anflluq_'r.:61 10.{T1.tn1uq0Lfl1.t0.3910 vasopressin ttqnql.lnu tT1.[ :3qunl:u9]o'lljo.iunooLnao
q a u e X ovlr a q uq Vl
tLo,tLuu?fiu.: nnrrutuonru nr[a rurnn?']n'tr14qlsr1fl0{un0otn0oLto.t[u14xto Lqr ttflrRil0.]dqe4oqea6lu6t-Xrn,.l0.1[14ufltfrtJo1Ail't L14un0q[fl09ttto.: Ll.[fix LattnrfrSJ0.lfto'tuo'] 1{0na'lnu vasopressin L3.Jtllil
q t a 4 - X v q U , o q eu q v d ^ a a Ynr:Ltooncit0ulunnrrtiiau? L0rrn: Lrunr Luue [0toutrlpJoa{il'];tfitJ0u epinephrine :?3J11.:
vasopressin ottvie.rndmnn:rflnr:yir CPCR riJuirnrururl\msrrrql0ufluo.Jta{ V1 receptorsA-,61 <r
Fl.t ?1 Ltu 0 u Lunl?r HJunT9t{zu ndr r rd u.: fi n utunr :td' vasooress i n 6 o rJ o q u r il u'.t #u u^, fft*tu firh u u n-.r or n'[v{nr.:
ql
A v a'Lq d q qe uq Y. Xflfl00tn00 nnl3Jtu014't [Qljretnoo 11.[fr1.[1mqno{fln{a-rn LuYt1.114? La T?3J?1.1o'la}lu[1.{oo'luLlfl3
rJfrfi3urnr:uvi 1Lonnson, 2003) oirriutuvrr.:rJfrri6oi"ru#srrunyttinr?rt4finrdrrnr:"lv{
v a s o p re s s i n yn.r u*': t o r fi o fl o.: nTu r.r n rir.: r 6 u r e-r n Fi r r
Itr:il..q
u X ou r6te , X, dle qe dq-rn{otntiLo.tqrlAtLnvnt:fl't:'tan'r:1.nLilLTil't.ton1.lnL.tT?'tn't:Ltvasopressin [uzungra
a i.qv a t i <'nirnr:t'i'epinephrine rr{:'ts vasopressin fiqvrfrvir'lv{ranoot6ooLto.:ai'luilortuqeir 6.tiflu
daodleavlr*XoqXXr1,.6leL6lvudoFl0Yt'1[14tfl091 Lilflils.]rLovnfl'l&Jruafi? LaSJ.lnlju u0ilatnu vasopressln ltj?1-l L14141Latqud ^ - r:r, -l qe a 6l u & q6l & a i
t:?'.l9r0.1fi')sttfl3 LeJtuliln'rTLTacnSto14LunnliltuaH? [0 :?tJ?1.] vasopressin ilzuntilx.JFr'rlj0.3
^ i' A & aa ' A X v a9t?LtLTUn1UT1.[OY]U.tU0nn1:tl^tlJlJUlJ0.tn]Tt09rT?O tTU t't:ty{}JlJU1O{Fr?-t3J9tU14fl09rtfl09rtt9r.l
tura-elo nr:rfiruduro.:rj3rurr*rfi0efililrfi'urflilo.r unryirtf:vuuHliuriuurfioon#uurvir.:ruvl e e & \1 d &q 6 v d v e a !t9lto.lt:?11,[ u0aul.:'Lrfiq1s.Jfi'.]'[unl{nlTtLlt?uJttflvfi9?ttl{?1u u.l9lo.]flnu'lt1^{}JLqiltunr:ri't
vasopressin'[:Jld'yrr.:efiflntunr:vir cPcR yn-rnrrv cpn Iquiarryrslu#o.:to.:zuodr.r16u.:Aquoqile
rfi o"Lrdsr rr:n ut vasopressi n eLr"L#Loi'o dr.: il n a q n-ufi ae
. i:.91 A' : 1oflff1501{0$
,
#uri' u-qfiiq fi. zs+e. Guidetine fl6n zoos. x'r:fi'r:nAfi n. 22(2): 180-181 .$
American Heart Association. 2000. Guidelines 2000 for cardiopulmonary resuscitation and
emergency cardiovascular care. Circulation. 102: 11-1384.
Ballew, K.A, 1997. Recent advance: cardiopulmonary resuscitation. BMJ. 3(14): 1462-1468.
KKU. Vet. J. Vol. 16 No.2 May - August 2006 43
Biondi-Zoccai, G.G.L., Abbate, A., Parisi, Q., Agostoni, P., Burzotta, F., Sandroni, C., Zardini,
P. and Biasucci, L. 2003. ls vasopressin superior to adrenaline or placebo in the
management of cardiac arrest? A meta-analysis. Resuscitation. 59:221-224.
Cao, L., Weil, M.H., Sun, H. and Tang, W. 2003. Vasopressor agents for cardiopulmonary
resuscitation. J. Cardiovasc. Pharmacol. Ther. B(2): 115-120.
Cole, S.G., Otto, C.M. and Hughes, D. 2003. Cardiopulmonary cerebral resuscitation in
small animals-clinical practice review. Part ll. J. Vet. Emerg. Crit. Care.13(1): 13-23.
Ditchey, R.V. and Lindenfeld, J. 1988. Failure of epinephrine to improve the balance
between myocardial oxygen supply and demand during close-chest resuscitation in
dog. Circulation. 78: 382-389.
Ganong, W.F.2001. Reviewof Medical Physiology. 12th edition. McGraw-Hill. U.S.A.870 p.
Guyton, A.C. and Hall, J.E. 2000. Textbook of Medical Physiology. 1Oth edition. W.B.
Saunders. Philadelphia. 1014 p.
Haldane, S. and Marks, S.L. 2002. Cardiopulmonary cerebral resuscitation: emergency
drugs and postresuscitative care. Comp. Cont. Educ. Pract. Vet " 2 (\: 922-931.
Johnson, T. 2003. Use of vasopressin in cardiopulmonary arrest: controversy and promise.
Comp. Cont. Educ. Pract. Vet. 25(6): 448-451.
Kass, P.H. and Haskins, S.C. 1992. Survival following cardiopulmonary resuscitation in dog
and cat. J. Vet. Emerg. Crit. Care. 2(2): 57-65.
Krismer, A.C., Lindner, K.H., Kornberge, R., Wenzel, V., Mueller, G., Hund, W.O., Oroszy,
S., Lurie, K.G. and Mair, P. 2000. Cardiopulmonary resuscitation during severe
hypothermia in pigs: does epinephrine or vasopressin increase coronary perfusion
pressure? Anesth Analg. 90(1): 69-73.
Lindner, K.H., Haak, T., Keller, A., Bothner, U. and Lurie, K.G. 1996a. Release of
endogenous vasopressors during and after cardiopulmonary resuscitation. Heart. 75(2):
145-1 50.
Lindner, K.H., Prengel, A.W., Brinkmann, A., Strohmenger, H.U. and Lurie, K.G. 1996b.
Vasopressin administration in refractory cardiac arrest. Ann. lntern. Med. 124(12):
1 061 -1 064.
Lindner, K.H., Dirks, B., Strohmenger, H.U., Prengel, A.W. and Lurie, K. 1997. Randomised
comparision of epinephrine and vasopressin in patients with oulof-hospital ventricu-
lar fibrillation. Lancet. 349(9051): 535-537.
44 x'rrd1:#nxLry,r?r€rFl'rflFri sJ?. fld ro qfud 2 r\qunrnru * Rtyrnru es+g
Stiell, 1.G., Hebert, P.C., Wellls, G.A., Vandemheen, K.L., Tang, A.S., Higginson, L.A., Dreyer,
J.F., Clement, C., Battram, E., Watpool, 1., Mason, S., Klassen, T. and Weitzman,
B.N. 2001. Vasopressin versus epinephrine for inhospital cardiac arrest: a randomised
controllecj trail. Lancet. 358(9276): 105-109
Swenson, M.J. and Reece, W.O. 1993. Duke's Physiology of Domestic Animals. 11th
edition. Cornell University Press. lthaca. 962 p.
Waldrop, J.E., Rozanski, E.A., Swanke, E.D., O' Toole, T.E. and Rush, J.E. 2004. Causes
of cardiopulmonary arrest, resuscitation management, and functional outcome in dog
and cat surviving cardiopulmonary arrest. J. Vet. Emerg. crit. care. la():22-zg.wenzel, V., Krismer, A.c., Lindner, K.H., Arntz, H.R., Sitter, H. and stadlbauer, K.H. 2000.
Survival with full neurologic recovery and no cerebral pathology after prolonged
cardiopulmonary resuscitation with vasopressin in pig. J. Am. Coll. Cardiol. 35: 527-533.
Wenzel, V. and Lindner, K.H. 2001. Employing vasopressin during cardiopulmonary resuscitation
and vasodilatory shock as a lifesaving vasopressor. Cardiovasc. Res. 51(3): 529-541.
Willmcs, C., Kirby, R. and Rudloff, E.2002. Cardiopulmonary resuscitation update: stepping
outside the box. Comp. Cont. Educ. Pract. YeL 24(lZ): 922-931.
Wingfield, W.E. and Van Pelt, D.R. 1992. Respiratory and carcliopulmonary arrest in dog
and cat: 256 case (1986-1991). J. Am. vet. Med. Assoc.2ao(2):1993-1996.
Woodhouse, S.P., Cox, S. and Boyd, P.'1995. High dose and standard dose adrenaline do not
alter survival, compare with placebo, in cardiac arrest. Resuscitation. 30: 243-249.
llt